Canton Strategic Holdings Inc (CNTN)
Canton Strategic Holdings Inc. is a biotechnology company listed on NASDAQ under the ticker CNTN. The company has said it is focused on using Canton Coin and supporting the Canton network to help advance institutional adoption of blockchain-based infrastructure and the digitization of financial markets. Its development efforts have also included GV104, a buccal film technology that completed a Phase 1 trial in military personnel and chemical incident responders, and GV023, an oral infliximab formulation designed to reduce the need for repeated intravenous treatment. The company was previously named Tharimmune, Inc. and adopted its current name in February 2026. Canton Strategic Holdings was founded in 2017 and is based in Red Bank, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CNTN
|
$3.03
|
31.9% Upside
|
Undervalued
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 13, 2026
|
0.4x
|
122.5x
|
182.5 M
|
146 M
|
0.0%
|
91.3%
|
0.3
|
23.1%
|
